

May 4, 2022

Notice Regarding Recalculated 340B Ceiling Prices for 2Q2020

Johnson & Johnson Health Care Systems Inc., (“JJHCS”) on behalf of Johnson & Johnson companies participating in the 340B program (Janssen Pharmaceuticals, Inc.) (“Janssen”) has asked the Office of Pharmacy Affairs (OPA) to post this notice on OPA’s public website to ensure transparency.

Janssen has revised 2Q2020 340B pricing on covered outpatient drugs. The revisions were due to standard restatements of Medicaid pricing data made to CMS. As a result of the recalculated 340B Ceiling Prices, Janssen has determined that, a refund is or may be owed to 340B Covered Entities that purchased any of the below NDCs during the period of April 1, 2020 through June 30, 2020.

Janssen will be communicating with and issuing refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B covered entities. If you feel you have not received an appropriate adjustment, please contact Janssen via email at: ra-hcsus-govcontract@its.jnj.com with a subject line of “340B Standard Refile” and your entities 340B ID. In addition, please include in the body of your email: NDC Number, Quantity, Original Purchase Invoice Number, Invoice Date, and the Wholesaler the product was purchased through for all affected products so that we can research your inquiry further.

NDC 11	NDC Description	Quarter/Year
10147-0951-03	PALIPERIDONE TAB,1.5MG,30S,12 CNT	2Q20
10147-0954-01	PALIPERIDONE TAB,9MG,HUD (2X5)X10,10CNT	2Q20
10147-0954-03	PALIPERIDONE TAB,9MG,30S,12CNT	2Q20
57894-0060-02	STELARA 45MG/VIAL 24CT	2Q20
57894-0060-03	STELARA 45 MG/0.5 ML ULTRASAFE PFS	2Q20
59676-0312-04	PROCRIT 10000 U/ML MD VIAL 4S	2Q20
66215-0103-56	TRACLEER 32MG 56 TABL. US	2Q20